All articles by Jay Patel

Jay Patel is a Pharma analyst with GlobalData.

89bio CMO touts advantages of pegozafermin following Phase III initiation

89bio recently revealed the initiation of the Phase III ENLIGHTEN-Cirrhosis trial of its flagship FGF21 analog, pegozafermin, in patients with…
Rezdiffra approval is a turning point for NASH, though challenges remain

The announcement by Madrigal Pharmaceuticals that its flagship asset Rezdiffra (resmetirom) had been approved in the US was a seismic…
Industry slow to embrace new fatty liver disease nomenclature

This June, three of the largest international liver societies—the European Association for the Study of the Liver (EASL), the American…
THR-β agonists emerge as leading drug class in NASH

Public interest in thyroid hormone receptor beta (THR-β) agonists in development for non-alcoholic steatohepatitis (NASH) has soared in recent months.…

Sections